However, the same group demonstrated one year later that treatment with the PPARα agonist fenofibrate inhibited tumor growth in syngenic LLC1 or B16 melanoma tumor bearing mice, due to an increase of TSP-1 and inhibition of tumor angiogenesis. The gene discussed is PPARA; the disease is neoplasm.